Skip to main content
Premium Trial:

Request an Annual Quote

New England Biolabs Licenses Genomic Health's Technology for RNA Depletion

NEW YORK (GenomeWeb) – New England Biolabs today announced it has licensed Genomic Health's technology for depleting abundant RNAs and has incorporated it for the first time in the NEBNext rRNA Depletion Kit.

The NEBNext line of products are reagents that facilitate RNA and DNA library preparation for next-generation sequencing.

According to NEB, depleting abundant RNAs is crucial for performing RNA-seq experiments at a lower cost. Ribosomal RNAs can constitute about 90 percent of total RNA and must be removed from a sample in order to focus on the RNA molecules of interest. Doing so can be especially difficult in low-input and formalin-fixed, paraffin-embedded RNA samples, and Genomic Health's technology, which uses RNase H-based depletion, addresses this challenge.

"The NEBNext rRNA Depletion Kits exhibits efficient removal of these abundant RNAs, reducing the number of sequencing runs required, and ultimately the overall cost of sequencing," Fiona Stewart, NEB's next-generation sequencing product marketing manager, said in a statement. She also noted that the kit incorporates a streamlined workflow and is optimized for inputs as low as 10 nanograms total RNA.

Financial and other terms of the deal were not disclosed.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.